Imagenebio Inc (IMA) Stock Price, Quote & News

Company Profile

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 858 345 6265

Website: www.inmagenebio.com

Address:

12526 High Bluff Drive, Suite 345, San Diego, United States

WallStArb Nov. 25 at 5:19 PM

$IMA exited some more 7.35 - 7.41 - derisking until I confirm the Wedbush reasoning why they expect it to be worth $2 or $25M market cap

0 · Reply

WallStArb Nov. 25 at 2:59 PM

$IMA sold a few I picked up yesterday @ 6.91 for 7.20 - 7.25 will wait to rebuy

1 · Reply

JarvisFlow Nov. 25 at 2:04 PM

Wedbush has adjusted their stance on ImageneBio ( $IMA ), setting the rating to Underperform with a target price of 2.

1 · Reply

J7263 Nov. 25 at 4:43 AM

$IMA no catalysts until q4 2026. Don't forget about the opportunity cost 😬.

1 · Reply

WallStArb Nov. 25 at 3:54 AM

$IMA sold off 9/4/25 because of Sanofi Amlitelimab P3 data, but IMG-007 Shows a Stronger Phase 2A Signal Than Sanofi’s Amlitelimab Among emerging biologics for atopic dermatitis, ImageneBio’s IMG-007 delivered a more impressive Phase 2A efficacy and durability signal than Sanofi’s amlitelimab at a comparable early stage — despite being tested in a much smaller, open-label cohort. While Sanofi’s program benefits from large, randomized datasets, the early-stage comparison favors IMG-007 on EASI-75, speed of response, durability off-treatment, and early tolerability. IMG-007 shows nearly double the EASI-75 response at a comparable Phase 2A timepoint. On a pure Phase 2A comparison, ImageneBio’s IMG-007 demonstrated a more promising efficacy and durability signal than Sanofi’s amlitelimab. If the upcoming Phase 2b data reproduce the Phase 2A profile, IMG-007 could emerge as a differentiated, potentially best-in-class non-depleting OX40 therapy for atopic dermatitis.

0 · Reply

WallStArb Nov. 21 at 6:40 PM

$KLRS i sold about 1/2 last few days $7 area. I am moving some into $IMA for a similar play but its a 9mo time horizon - trades at a nice 40% discount to NET CASH (about $12 a share as of today) - good upside for a big market (Dupixent & IL-4 / IL-13 Biologic is SOC for older - IMG-007 is non-depleting anti-OX40 mAb - less frequent dosing and better tolerability). Good upside and no real need to dilute for cash - downside is that Phase 2B data not expect until Q4 2026. Potential partner catalyst and they submitted protocol amendment for IMG‑007 Phase 2B

0 · Reply

WallStArb Nov. 21 at 6:21 PM

$IMA Valuation Framework (Atopic Dermatitis Only): three scenarios: Base Case (Most Probable) P2b shows clear efficacy improvement vs P2a EASI-75 in 50–65% range at Week 16 Dosing every 4–8 weeks proves viable Safety remains clean Probability of success (P2 → Launch): 35% Peak AD sales: $1.5–2.0B Discount rate: 12–15% Implied Risk-Adjusted NPV: $400–650M Bull Case (Strong P2b Data) EASI-75 ≥ 70% Very strong durability 8–12 week dosing viable Becomes credible mid-tier competitor to Dupixent, Adbry, lebrikizumab Probability of success: 45–50% Peak sales: $2.5–3.5B Risk-Adjusted NPV: $900M – $1.6B Bear Case (P2b mixed or underperforms) Assumptions Efficacy modest (EASI-75 < 45%) Duration inconsistent Safety concerns or exposure-limiting AEs PoS: 10–15% Peak sales: ~$800M upper bound Risk-Adjusted NPV: $120–200M

0 · Reply

WallStArb Nov. 21 at 6:12 PM

$IMA Phase 2b (ADAPTIVE) — Why the Setup Looks Strong: The company is implementing a protocol amendment designed to: Optimize dosing Add loading dose(s) Adjust dose intervals based on half-life Enhance patient convenience Expand the therapeutic window This is not a typical amendment — it's a mechanism-driven optimization leveraging the long half-life and prior exposure-response data. If exposure–response analyses continue to support higher early exposure (loading → sustained trough), IMG-007 could produce materially improved efficacy over P2a. Given that derivation, Phase 2b has a good chance of reading out better than P2a on absolute terms.

0 · Reply

WallStArb Nov. 21 at 5:38 PM

$IMA ImageneBio Updates Phase 2b Trial for Atopic Dermatitis In their Q3 2025 10‑Q filing, ImageneBio announced a strategic protocol amendment to the ongoing Phase 2b ADAPTIVE trial of IMG‑007, their differentiated non-depleting anti-OX40 monoclonal antibody for moderate-to-severe atopic dermatitis. Key updates include: Expanded dosing regimens to explore a broader dose/exposure range Incorporation of loading doses to enhance early efficacy Patient-friendly dosing intervals leveraging IMG‑007’s long half-life Optimized trial design to better evaluate both short-term and durable responses Why it matters: Enhances the probability of robust, durable efficacy Further de-risks the program ahead of the Q4 2026 Phase 2b readout This amendment positions IMG‑007 as a potentially differentiated next-generation biologic for AD, with a clear, mechanism-driven strategy to maximize efficacy and patient convenience.

0 · Reply

WallStArb Nov. 21 at 5:35 PM

$IMA accumulated starter position last couple days yesterday 7.15 area and today similar # 6.90 - 7.05. expect a decent Jan/Feb effect as the selling overhang starts to abate after year end (11/30 for most funds) - wouldn't shock me to see a small Santa rally/Jan effect into Feb and looking for $12 - $14 area

0 · Reply

ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team

Nov 6, 2025, 8:30 AM EST - 4 weeks ago

ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences

Aug 1, 2025, 4:15 PM EDT - 4 months ago

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 25, 2025, 11:00 AM EDT - 4 months ago

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

Jul 23, 2025, 9:00 AM EDT - 4 months ago

Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

PSTX

Jul 15, 2025, 4:15 PM EDT - 5 months ago

Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals

Jul 11, 2025, 8:00 AM EDT - 5 months ago

Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals

Dec 23, 2024, 8:37 AM EST - 1 year ago

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ikena Oncology Reports Third Quarter 2024 Financial Results

Aug 8, 2024, 4:15 PM EDT - 1 year ago

Ikena Oncology Reports Second Quarter 2024 Financial Results

May 28, 2024, 4:42 PM EDT - 1 year ago

UPDATE – Ikena Oncology Announces Strategic Update

May 28, 2024, 4:15 PM EDT - 1 year ago

Ikena Oncology Announces Strategic Update

May 13, 2024, 4:45 PM EDT - 1 year ago

Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 27, 2024, 8:00 AM EST - 1 year ago

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

Feb 21, 2024, 4:15 PM EST - 1 year ago

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Jan 18, 2024, 4:05 PM EST - 2 years ago

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

Nov 9, 2023, 7:00 AM EST - 2 years ago

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Nov 7, 2023, 8:00 AM EST - 2 years ago

Ikena Oncology to Present at Multiple November 2023 Investor Conferences

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Ikena Oncology to Participate in September 2023 Investor Conferences

Aug 10, 2023, 8:00 AM EDT - 2 years ago

Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

May 24, 2023, 8:00 AM EDT - 2 years ago

Ikena Oncology to Participate in Upcoming Investor Conferences

May 15, 2023, 7:50 AM EDT - 2 years ago

Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline

May 15, 2023, 7:45 AM EDT - 2 years ago

Ikena Oncology Announces $40 Million Underwritten Offering

Apr 20, 2023, 8:00 AM EDT - 2 years ago

Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Apr 17, 2023, 9:00 AM EDT - 2 years ago

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

Mar 14, 2023, 7:00 AM EDT - 2 years ago

Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 7, 2023, 8:00 AM EST - 2 years ago

Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting

Mar 6, 2023, 8:00 AM EST - 2 years ago

Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma

Feb 28, 2023, 8:00 AM EST - 3 years ago

Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference

Dec 19, 2022, 4:30 PM EST - 3 years ago

Ikena Oncology Appoints Owen Hughes as Board Chair

Nov 28, 2022, 8:00 AM EST - 3 years ago

Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update

Nov 22, 2022, 7:30 AM EST - 3 years ago

Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference

Nov 10, 2022, 9:00 AM EST - 3 years ago

Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma

Nov 7, 2022, 8:48 AM EST - 3 years ago

UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Nov 7, 2022, 8:05 AM EST - 3 years ago

Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Oct 26, 2022, 7:30 AM EDT - 3 years ago

Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance

Oct 18, 2022, 7:30 AM EDT - 3 years ago

Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway

Oct 5, 2022, 8:05 AM EDT - 3 years ago

Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Sep 6, 2022, 7:30 AM EDT - 3 years ago

Ikena Oncology to Participate in September 2022 Investor Conferences

Aug 11, 2022, 7:30 AM EDT - 3 years ago

Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Jul 6, 2022, 7:00 AM EDT - 3 years ago

Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022

Jun 22, 2022, 7:00 AM EDT - 3 years ago

Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma

May 18, 2022, 7:00 AM EDT - 3 years ago

Ikena Oncology to Participate in Spring 2022 Investor Conferences

May 12, 2022, 7:00 AM EDT - 3 years ago

Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update

May 3, 2022, 8:00 AM EDT - 3 years ago

Seismic Therapeutic Appoints Maude Tessier, PhD, as Chief Business Officer

May 2, 2022, 7:00 AM EDT - 3 years ago

Ikena Oncology and Vall d'Hebron Institute of Oncology Announce Research & Development Collaboration

WallStArb Nov. 25 at 5:19 PM

$IMA exited some more 7.35 - 7.41 - derisking until I confirm the Wedbush reasoning why they expect it to be worth $2 or $25M market cap

0 · Reply

WallStArb Nov. 25 at 2:59 PM

$IMA sold a few I picked up yesterday @ 6.91 for 7.20 - 7.25 will wait to rebuy

1 · Reply

JarvisFlow Nov. 25 at 2:04 PM

Wedbush has adjusted their stance on ImageneBio ( $IMA ), setting the rating to Underperform with a target price of 2.

1 · Reply

J7263 Nov. 25 at 4:43 AM

$IMA no catalysts until q4 2026. Don't forget about the opportunity cost 😬.

1 · Reply

WallStArb Nov. 25 at 3:54 AM

0 · Reply

WallStArb Nov. 21 at 6:40 PM

0 · Reply

WallStArb Nov. 21 at 6:21 PM

0 · Reply

WallStArb Nov. 21 at 6:12 PM

0 · Reply

WallStArb Nov. 21 at 5:38 PM

0 · Reply

WallStArb Nov. 21 at 5:35 PM

0 · Reply

WallStArb Nov. 19 at 8:32 PM

$IMA https://clinicaltrials.gov/study/NCT07037901

0 · Reply

WallStArb Nov. 19 at 8:31 PM

$IMA http://archive.fast-edgar.com/20251119/A72BBQ2EZZ2RKZZU22ZI2ZYRGDMNZZ22Z27G/d834017dex991.htm

0 · Reply

WallStArb Nov. 14 at 7:04 PM

$IMA ImageneBio significant upside optionality tied to its Phase 2b program, IMG‑007, in moderate-to-severe atopic dermatitis. The company has ~$130M in net cash/near-cash, providing a strong runway. Using a probability-weighted, risk-adjusted NPV framework, the pipeline fair value is estimated around $45 per share, well above the current trading price of ~$8. Notably, the current share price is materially below the implied valuation of ~$30/share paid by PIPE investors last winter, despite the broader biotech sector (XBI) being up 50%+ over the same period. This divergence highlights that the market has not yet priced in the pipeline or upcoming Phase 2b readout, expected in 2027, creating potential for substantial upside. Recent PIPE investors—including DeepTrack, Foresite Capital, RTW Investments, BVF Partners, Blue Owl Healthcare Opportunities, Omega Funds, and OrbiMed—participated at a premium to today’s price, signaling strong conviction from specialist biotech capital.

0 · Reply

WallStArb Nov. 14 at 6:48 PM

$IMA Net Cash & Near-Cash: ~$130M (~$10/share), providing a strong financial runway. Pipeline rNPV: Bad outcome (~45% probability) → pipeline ~$0/share Partial outcome (~40% probability) → pipeline ~$70/share Strong outcome (~15% probability) → pipeline ~$112/share Weighted Expected Value: Pipeline contribution ≈ $45/share Add net cash → probability-weighted fair value ≈ $45/share (pre-dilution) Timeline: Topline Phase 2b readout expected in 2027 Current market price (~$8/share) reflects minimal pipeline value Upside Potential: Even after potential dilution (~$75M raise), probability-weighted fair value suggests ~5–6x upside Strong readout could rerate shares toward full risk-adjusted NPV (~$140/share) Institutional Backing: Recent PIPE included specialist biotech investors like DeepTrack, highlighting confidence from experienced, high-conviction biotech capital

0 · Reply

WallStArb Nov. 14 at 6:46 PM

$IMA IMA trades at ~$8/share, largely reflecting its $130M cash ($10 a share), while the Phase 2b IMG‑007 readout isn’t until 2027. Using a probability-weighted rNPV approach, we estimate a fair value around $45/share, reflecting upside from partial or strong efficacy. Notably, the recent PIPE brought in specialist biotech investors including DeepTrack, Foresite Capital, RTW Investments, BVF Partners, Blue Owl Healthcare Opportunities, Omega Funds, and OrbiMed, signaling confidence from experienced, high-conviction capital. For those who follow binary catalysts, this is a classic early-stage biotech optionality play.

0 · Reply

WallStArb Nov. 4 at 3:46 PM

$IMA bought some yesterday 8.20 area

0 · Reply

WallStArb Oct. 28 at 8:21 PM

$IMA been accumulating in the 7.60 -8.20 area

0 · Reply

Livinglifewithlivingston Oct. 28 at 6:47 PM

$IMA

0 · Reply

BioTechHealthX Oct. 26 at 8:45 AM

$IMA One analyst projects a $276 target for ImageneBio. This company could be the next biotech moonshot. Read the full story here. https://biotechhealthx.com/biotech-news/imagenebio-ima-targets-3634-upside/

0 · Reply

Countercontrarian Oct. 25 at 9:23 AM

$IMA long @7.99

0 · Reply

notreload_ai Oct. 24 at 1:41 PM

Leerink rates $IMA stock Outperform with $30 target, calling it "undervalued." https://notreload.xyz/imagenebio-analysts-see-massive-upside/

0 · Reply

resistancebreakers Oct. 24 at 12:24 PM

$IMA 🖥️ing 🪖🫡☝️

0 · Reply

Market Cap	72.35M
Revenue (ttm)	3.50M
Net Income (ttm)	-49.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	47,300
Avg Vol	71,802
Day's Range	N/A - N/A
Shares Out	11.18M
Stochastic %K	21%
Beta	0.44
Analysts	Sell
Price Target	$16.00